ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 963,63
0,12%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Annexon Inc (ANNX)

  7. Annexon Inc (ANNX) Actualités

ANNX Annexon Inc

5,10
0,44 (9,44%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Annexon Inc ANNX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,44 9,44% 5,10 06:00:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,75 4,69 5,06 4,88 4,66
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202415:00GLOBETurnstone Biologics Appoints William Waddill to its Board of..
21/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202421:15EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:12EDGAR2Form 144 - Report of proposed sale of securities
15/2/202402:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202401:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202401:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202421:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202401:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202421:45EDGAR2Form 144 - Report of proposed sale of securities
12/2/202421:41EDGAR2Form 144 - Report of proposed sale of securities
12/2/202421:39EDGAR2Form 144 - Report of proposed sale of securities
23/1/202423:00EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
23/1/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:09EDGAR2Form 8-K - Current report
08/1/202402:00GLOBEAnnexon Outlines 2024 Priorities with Late-Stage Clinical..
29/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:50EDGAR2Form 144 - Report of proposed sale of securities
27/12/202312:30GLOBEAnnexon Biosciences to Present at the 42nd Annual J.P...
22/12/202323:28EDGAR2Form 8-K/A - Current report: [Amend]
21/12/202322:09EDGAR2Form 8-K - Current report
21/12/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/12/202323:27GLOBEAnnexon Announces Pricing of $125.0 Million Underwritten..
20/12/202323:24EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
20/12/202323:17EDGAR2Form 8-K - Current report
20/12/202323:10GLOBEAnnexon Outlines Global Registrational Program for ANX007 in..
20/12/202323:08GLOBEAnnexon Reports Phase 1 Results for ANX1502, its Oral Small..
18/12/202322:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
22/11/202322:01GLOBEAnnexon Biosciences to Participate in the 6th Annual..
13/11/202322:10EDGAR2Form 8-K - Current report
13/11/202312:30GLOBEAnnexon Reports Significant Progress with its Priority..
09/11/202312:30GLOBEAnnexon Biosciences to Participate in 2023 Jefferies London..
24/10/202322:30EDGAR2Form 8-K - Current report
24/10/202312:30GLOBEAnnexon Receives PRIME Designation from the EMA for ANX007..
18/10/202322:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
11/10/202322:44EDGAR2Form 8-K - Current report
10/10/202312:30GLOBEAnnexon Announces Clinical and Regulatory Progress for..
19/9/202312:30GLOBEAnnexon Biosciences to Participate in the 2023 Cantor Global..
18/9/202322:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..
07/8/202322:12EDGAR2Form 8-K - Current report
07/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202312:30GLOBEAnnexon Highlights Recent Pipeline and Business Progress and..
02/8/202323:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202323:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/8/202322:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..

Dernières Valeurs Consultées

NASDAQ
ANNX
Annexon
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés